 | |
 | |
| Names | |
|---|---|
| IUPAC name [(1-Methyl-2-oxoindol-3-ylidene)amino]thiourea | |
| Other names Metisazone | |
| Identifiers | |
3D model (JSmol) | |
| ChEMBL | |
| ChemSpider | |
| ECHA InfoCard | 100.016.016 |
| EC Number |
|
| KEGG | |
| MeSH | D008720 |
| UNII | |
| |
| |
| Properties | |
| C10H10N4OS | |
| Molar mass | 234.28 g/mol |
| Pharmacology | |
| J05AA01 (WHO) | |
Except where otherwise noted, data are given for materials in theirstandard state (at 25 °C [77 °F], 100 kPa). | |
Methisazone (USAN) ormetisazone (INN)[1] is anantiviral drug that works by inhibitingmRNA andprotein synthesis, especially in pox viruses. During trials in the 1960s it showed promising results againstsmallpox infection, but widespread use was considered logistically impractical in the developing countries facing smallpox cases, and it saw only limited use. In developed countries able to cope with the logistic challenge, treatment of smallpox could be achieved just as effectively withimmunoglobulin therapy, without the severe nausea associated with metisazone.[2]
Methisazone has been described as being used in prophylaxis since at least 1965.[3][4]
The condensation of N-methylisatin withthiosemicarbazide leads to methisazone.[citation needed]
 | Thisantiinfectivedrug article is astub. You can help Wikipedia byexpanding it. |
